Reimbursement Changes for Compounded Medications
Published Online: Thursday, April 24, 2014
In this video, David G. Miller, RPh, executive vice president and CEO of the International Academy of Compounding Pharmacists (IACP), discusses changes in insurance reimbursement for compounded medications.
This video was recorded at the National Community Pharmacists Association 115th Annual Convention in Orlando.
The FDA has granted approval to Genzyme’s eliglustat (Cerdelga), the only first-line oral therapy for patients with Type 1 Gaucher disease.
Grocery store chain joins growing list of major companies offering enhanced specialty pharmacy.
Ambulatory pharmacy practice will grow independent of community pharmacy practice, unless efforts are made to bring them closer together.